In the stomach and gut, GLP-1 binding impacts the smooth muscle and nervous system, acting to reduce muscle contractions and allowing food to stay in the stomach longer
In the subsequent phase III STEP trials of semaglutide, 2.4 mg once weekly, carefully up-titrated over 20 weeks, average weight losses of up to 18% were achieved over 68 weeks in people with obesity (start weight 107 kg) [40]
Contact Superpharma Group today to discuss Retatrutide API sourcing and bulk supply solutions.
Breaking that medicine into smaller doses would make it hard to measure a consistent dose and increases your risk of infection (from reusing the syringe)
Manuscript under review
Finally, similar to GLP-1 RAs, the medication should not be used in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [31, 43]